



**National Institute for
Health and Clinical Excellence**

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: 0845 003 7780
Fax: 0845 003 7784

Email: nice@nice.org.uk
www.nice.org.uk

Sent via email

██████████
Managing Director
Pierre Fabre

21 April 2011

Dear ██████████

Final appraisal determination: vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Thank you for your letter of 15 April 2011. This letter represents the final decision on initial scrutiny.

My view remains as set out in my first letter: Points 1.1(b), 1.1(d), 1.2(a) and 1.2(c) will proceed to an oral hearing. The remaining points are not valid grounds of appeal and will not be heard.

I note your query as to what happens following the decision of the Appeal Panel. If the Appeal Panel finds in favour of an appellant it is typical for them to refer the relevant section(s) of the guidance in question back to the Appraisal Committee for its reconsideration. However, this does not happen automatically and the Appeal Panel is free to ask for whatever steps it thinks fit to be taken.

Yours sincerely

██████████
Appeals Committee Chair
National Institute for Health and Clinical Excellence